Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C.

Rayhill SC, Barbeito R, Katz D, Voigt M, Labrecque D, Kirby P, Miller R, Stolpen A, Wu Y, Schmidt W.

Transplant Proc. 2006 Dec;38(10):3625-8.

PMID:
17175350
2.

Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.

Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, López-Andujar R, Moya A, Pareja E, Montalva E, Yago M, de Juan M, Mir J, Prieto M.

Transplantation. 2010 Dec 15;90(11):1204-9. doi: 10.1097/TP.0b013e3181fa93fa.

PMID:
21068701
3.

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.

Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ.

Liver Transpl. 2002 Jan;8(1):40-6.

4.

Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.

Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.

Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.

PMID:
18773960
5.

REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C.

Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R; REFINE Study Group.

Am J Transplant. 2014 Mar;14(3):635-46. doi: 10.1111/ajt.12620. Epub 2014 Jan 23.

6.

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.

Transplantation. 1997 Dec 27;64(12):1755-60.

PMID:
9422416
7.
8.

Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.

Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA.

Pediatr Transplant. 2003 Jun;7(3):217-22.

PMID:
12756047
9.

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.

Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, Markmann JF, Drazan KE, Holt C, Imagawa D, Goldstein LI, Martin P, Busuttil RW.

Ann Surg. 1999 Jun;229(6):824-31; discussion 831-3.

10.

Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.

Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.

Transplantation. 2013 Feb 27;95(4):629-34. doi: 10.1097/TP.0b013e318277e378.

PMID:
23423270
11.

A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.

Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.

Transplantation. 2012 Feb 27;93(4):437-43. doi: 10.1097/TP.0b013e31824215b7.

PMID:
22228415
12.

Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database.

Irish WD, Arcona S, Bowers D, Trotter JF.

Am J Transplant. 2011 Aug;11(8):1676-85. doi: 10.1111/j.1600-6143.2011.03508.x. Epub 2011 May 12.

14.

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.

Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR.

Liver Transpl. 2005 Jul;11(7):750-9.

15.

Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.

Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J.

Clin Transplant. 2007 Jul-Aug;21(4):526-31.

PMID:
17645714
17.

Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.

Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.

Am J Gastroenterol. 1997 Sep;92(9):1453-7.

PMID:
9317061
18.

Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.

Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, Ojogho OK, So SK, Frerker M, Castillo RO, Monge H, Esquivel CO.

Pediatr Transplant. 1999 Feb;3(1):22-6.

PMID:
10359027
19.

Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.

Morrissey PE, Gohh R, Shaffer D, Crosson A, Madras PN, Sahyoun AI, Monaco AP.

Transplantation. 1997 Mar 27;63(6):845-8.

PMID:
9089224
20.

Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.

Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, Shiffman ML, Luketic VA, Contos MJ, Mills AS, Ferreira-Gonzalez A, Posner MP.

Clin Transplant. 2004 Aug;18(4):463-72.

PMID:
15233827
Items per page

Supplemental Content

Write to the Help Desk